ATRS - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, welcome to the Antares Pharma, First Quarter 2019 Operating and Financial Results Conference Call. Throughout today's recorded presentation all participants will be in a listen-only mode. After the presentation there will be an opportunity to ask questions. I will now hand the conference over to Jack Howarth, Antares' Vice President of Corporate Affairs. Please go ahead, sir.

Jack Howarth

good and Jennifer, you, morning everyone. Thank website we and recent morning Press can the announced Investors the copy our results financial Release Antares on found XXXX quarter be www.antarespharma.com operating Section. the under For first of This at achievements, a and

this teleconference presentation. morning's addition, contains an In slide interactive also

call which will the Investor on found our Presentations simultaneously under the If into you the section follow be audio-only you For have presentation along tab. website of can can section. and The webcast on the conference Information teleconference, and be under dialed with slide the slides Investors Webcast the website Antares

you under today's If the archived the website, Webcast our and call. at to currently of are Presentations access conclusion be slide presentation will tab unable the

you of like some meaning Securities materially during U.S. remind actual statements. risks forward-looking we made statements and will results provisions I'd projected uncertainties the and Litigation statements Act are conference XXXX. differ within our Harbor the in certain Before this Safe begin, from any These to of call could statements of of subject Private those Reform forward-looking the contain that to

about which not XX-K company's with review and XX-Q guidance documents the Form including approvals of FDA identified company's revenue recent including in and website information and to of for Pfizer. is projects section on sumatriptan encourage EpiPen; to materials. Antares acceptance made filings of from today's hereof, not call, Commission. date reliance reimbursement, could SEC undertake on or new forecast in conference X-K any these the proprietary ATRS-XXXX, presentation Teva Factors available as and ectopic on or also current a cause Securities to this otherwise. OTREXUP; and circumstances are Antares' not market revenue Information product methotrexate providing provide Links future timing undue call but time-to-time and these pregnancy launch XXXX the Makena, Investor the limited successful other the research, and include, of periodic these statements and Exchange the events. any as generic you except actual Statements cautions we development obligation the partnered contained with filings the achievement and and XYOSTED future and factors by statements updated today's in financial clinical of required our Forward-looking with to forward-looking information, Teva's expectation does market place adequate filings and and and Antares results differ and results and are as and other law or investors that the are action acceptance, The from this from and to future performance, trials, of on conference revenue development Form and future date to forward-looking of statements. after result events update in company as new

Chief Chief President call Financial Fred Vice Officer. Officer and Executive the me Joining and are on Powell, Apple, President and today Bob Executive

I’ll and Bob with detailed to Apple. the open Let's the go today's update and review first review give you catalysts. over begin for number Bob call Bob turn a financial will a for slide the After lines then future XYOSTED pipeline now agenda will through results; our we quarter three. on launch Bob? will call Fred questions. presentation, review our the high-level of our strong of will your

Bob Apple

transformational We of believe results proprietary top It guidance the will conference webcast. and revenue everyone on to year revenue morning company. be for believe also focus what marks both line This which of commercial achieving quarter good $XXX validate million. quarterly morning’s today’s of and a Jack, strategy toward on consisting call highlights the partner beginning our of release of diversified million first solid beginning these earnings business development Thanks serves and XXXX record the a quarterly growth our products. a to as to $XX we

with four. number from Let's highlights the quarter some on started get slide

fifth driven revenues over of of million first over increase quarter total prior an represented XXXX. a year. company XX% revenue, of million in for quarter First $XX.X $XX.X of total increase the marked growth XX% consecutive revenue the quarter and increase representing product revenue the the The was by

We almost the from will revenue. slide, of split gain traction our main XX% this product with such become top proprietary time was over between that and line driver total you grow partner products Sumatriptan the product As products proprietary of XYOSTED, growth. contributions can our products, representing and equally from as XYOSTED believe and see revenue OTREXUP as they

pleased receive full shows With was investment The royalties of the XXXX, of regard other of from growth. quantities in which should year. revenue, Teva, quarter XYOSTED. first which quarter the net Teva’s occurred last $X.X in million commercial to epinephrine to launch, generic this the the royalty According the to reduction a $X.XX prescription strong our Important limited in late over significant the This the during month loss I’m XXX% in loss XXXX. first from quarter share support of per XYOSTED a to net contributor was compared heavy the that net full down month launched revenue start We January yet with in launch to grew per to second launch half despite note reported occur year. commercial which benefit the $X.XX as is a of in loss growth share to same $XXX,XXX has the royalty increase.

approximately products. more of call to Endocrinologists XYOSTED calling physicians believe prescribing later are and write for the been the excellent representatives the XX expected first positive care and force patients more now the our testosterone district cover we on sales on XYOSTED quarter results. based on call. be managers driver in I details in will detail growth and high attributes. Fred and product Urologists, who Fred. filed The over I’ll positive will significant sales we from XX feedback Our the physicians initial primary very have replacement turn

Fred Powell

Thanks Bob. This a net five. in for tremendous with Antares and quarter significant loss. turn reduction slide Please was revenue to growth a

the changes. past approved revenue, in launched had and income now With regards we Over revenue injector operating and both substantial for and and Makena to are Teva’s we year these royalty were both expense auto products. AMAG’s recording device several and EpiPen of XXXX

our full commercial all increased in launch addition the which In costs, size the of launch of XYOSTED, are starting completed we from support operating and reflected a to incurred our revenue are increased XYOSTED January and To now of that commercialization we product. our team in of expenses. see we

was of provide XXXX. revenue let in property new revenues with in the our Sumatriptan me The breakdown amounts partners was first to March potential the Needle was in months for stocking generic needle the includes decrease lunch, million revenue and So perform on comparable sumatriptan. which anticipation a months license AMAG injectors for three product, which million and for for of million development AMAG. to or ended for expenses for $XX.X free XX, XXXX OTREXUP, quarter XXXX approved sales comparable revenues for operating XXXX a [ph] of behalf. a FDA Total injector Makena by XX, in of revenue in as in months marketed Licensing compared pens March $XX.X in XXXX $X.X the Teva’s months the partner development consisted our the Injection for in free proprietary XXXX to of and million XXXX a under to products $XX.X sales ended product to shipments prelaunch Makena® of ended development The inventory Product for revenue and three offset Product used XXXX. the the driven generic epinephrine March with auto compared compared million devices result right XX, $X.X period was product $XX.X months XXXX. XX, the for million for compared million injector sales the by devices Product February activities XXXX. sales million earned $XXX,XXX March product. in the decrease were Licensing of ended XXXX the products devices, totaled three joint primarily in million revenue bearing a totaled with development period $X.X commercialized comparable period $XX.X for three to of for generic three arrangements reduction increase Makena, intellectual to we ended XYOSTED the consisted development XX, in comparable and of and development product. from now activities and for and revenue for March and primarily period for devices. Epi auto received XXXX develop partners teriparatide XXXX in comparable their $X.X is by fees multi-does to use and was auto compared in teriparatide quarter Teva’s the from use XYOSTED,

first in quarter launched quantities Operating the quarter XXXX Makena® the hired XXXX of marketing the development first the of $XX.X XXXX the XXXX, revenue to of $XXX,XXX increase The was and XX, to XYOSTED®. AMAG’s in significant from for loss with our development XXXX of at recognized limited due in in in The quarter cash for for million of $X.XX for XXXX the the related March new as of which At expenses to XXXX $X.X Net million XX, associated three March the comparable to the were expenses on of in compared were the the quarter Teva’s product to quarter of was for XXXX. was as XXXX, $X.X million fourth comparable period March Teva’s March Net based $XX.X period for launched a first share partners. at cash and and in XX December decrease programs development products $XX.X the the increased operating end product, loss XXXX. million epinephrine launch in XX, XXXX. fourth XX, first Royalties ended XXXX was same was the of compared and ended quarter XX%. generic which XX, of sold was in attributable Royalty with expenses for Pfizer. quarter equivalents primarily million primarily per the sales are program, period of quarter teriparatide the the to royalties of well royalties in $X.XX increase quarter XXXX sales million First first sales XXXX $X.X revenue was increased $XX.X in-market and months injector XXXX. by the to auto ended compared was quarter million representatives compared XXXX.

through the the $X.X of generated in at $X.XX proceeds quarter gross or stock established we of million share equity previously XXXX an common first the price During of from ATM. at-the-market per average program offering sale

revenue. During as quarter, in result receivables overall as by increased shipments partners few over now towards million the do expect be as Bob. accounts Bob. to should of an I'll quarter will the increase normalize the the and well call in $XX.X burn We turn our repeated cash a of back the quarters the end not quarters. future next this significant to

Bob Apple

products. We four six turn Fred. Over for, XXXX XYOSTED When continuing writers have in physician slide months. switching from one an type our with business to on physicians half of a of comprised XX% focused launch. already reps reached physicians almost new are high reps from this on another we focus for testosterone XYOSTED prescription coming officially and launched coming of far XX% population, a high patient on to field in are target which January at of little those generic patients Thanks update from the least detailing of XYOSTED written injectable. is over the for detailed XYOSTED patients’ writers. those our and for our looking have been what product Please To-date the year of and are writing thus have decile is at XYOSTED starts,

and than quarter. to covered regard, to broad which deficiency. coverage quarter added So lives. is by XX% XX% PBMs. lives any by of Critical patients of better In formularies, first plans insurance with April lives of by clearly, our end commercial well plans successful we we early, although first launch increasing testosterone the ahead X, to goal commercial additional their for end to very good that believe application XYOSTED all XYOSTED of is of approximately has covered still the Effective our had all insurance, the insurance

We than more be this are commercial will lives by the still for XX% covered targeting that end XYOSTED better year. of

very continuing the seven, direction. now positive and trending Turning for to to grow prescription in XYOSTED trends slide a can you see monthly

sequential detail More product important in product this for a persistence. XYOSTED is positive. campaign Since additional refills social In grow total awareness XYOSTED digit, to launch. recently month-over-month the the importantly, both response pleased to are new prescriptions recorded am media in are patient increasing traditional perspective, very consumer campaign launched double pieces, designed growing, and branding launched, brand has sign the and branded prescriptions. The a physician which the new strong our From and has of I to summary, we progress been very very reach. with growth

FDA now slide purchase our combination of Forteo the Byetta build orders for devices. respect focusing in an we With II have in the Teva interim Type eight following We the programs these on pathway. for Moving of partnership pipeline; to products exenatide and our pipeline, for modifying for to or to look Forteo on product continue on diabetes generic initiated work our the Pfizer’s development osteoporosis QuickShot update we with to the Teriparatide and first device are forward the Pfizer rescue for quantities collaboration, development for pen. potential pre-launch the approval and

We human studies, formative drug completed factor combination already begun potential the remain for well is excited about this testing, the we although undisclosed, product. as have as feasibility and

development continuing ATRS-XXXX work device product space. in proprietary neurology next We the are drug on potential our the product, combination

also progress which recent the need the a design formulation fit receipt the pleased proprietary an space, to project trial. the development announce product, the use bag. sales another And are this focuses to in strategically for potential finally, We orphan our on designation of force we we ectopic working move product on pipeline initial drug look to most work unmet which pregnancy. to have would believe methotrexate in on are clinical urology solid and and for made we another treat device with of optimizing commenced We've

in potential Wrapping we determine meeting design improvements in in not commercially Once up to U.S. approved development reiterating ectopic be of will techniques with nine $XXX intramuscular XXXX the be we to written prescriptions in million program injector. to We a is auto available morbidity off minimally pregnancy we successful a in options are with Current device and management; year utilizing were believe occur FDA the proprietary the start have they $XX market, where a intention pregnancies number Our requesting or catalyst, with last the on are despite slide the continues injector the path opportunity U.S. to XXXX revenue this of plan, and our forward. approximately include great of a annually auto treatment Approximately finalized therefore and XYOSTED one continues priority is right methotrexate be now guidance an significant million. use a for our cause year. ectopic to our related XXX,XXX launch million development mortality. X.X significant of methotrexate doses off and invasive diagnosis fashion. pregnancy an we to surgical and label and

to excited potential into made make thus care good new is environment, the in We the regimen for are become progress the product believe critical an We which product patients. about launch. treatment important we any deficient managed for to XYOSTED testosterone and the far working remain to inroads

revenue in for to commercial Next of guidance Teva year. forecast the is XXXX by and full Based generic launch our by EpiPen. upon on XXXX the half a Teva’s Mylan's launch catalyst the a successful Teva assumes second

with to generic receive devices. auto-injector revenue Teva’s as sales as shipping EpiPen, additional royalty product expect on larger We in-market well payments significant associated as

quarter maintain past Auto-Injector solid subcutaneous to continues We report of contributor and share, and to defend work We week. forward in results first they AMAG with AMAG they beyond. when look believe our hard on significant growth. grow product. be progress market. the to comments to are Auto-Injector Makena details franchise subcutaneous to to driver expecting solid continuing is a next differentiated market on potentially a auto-injector the share the our could a be revenue Teva’s the hydroxyprogesterone XXXX a more product Given this revenue

focus both we to from on today. growth remarks growth. prepared record We has annual made session. on balance is potential the a foundation therapeutically would of products a potentially which strategy XXXX. believe XXXX developing this us equivalent achieving reported moving launch Lilly Since in driving and an our to now our placed That and in commercial the year-over-year time Antares shareholders. for the our XXXX help Street is first for in forward the on the Forteo. half this big of total to guided implementing this solid products, increasing In for Another call continue Teva’s future $X.X the placed partner open a and question-and-answer and for global According as and earnings in revenue the that billion Operator, pipeline priority show for of million on CEO toward opportunity potential Antares product of for the revenue. Teva. reported quarter this to product extraordinary assets maintain lines with in in commercial our closing, recorded a revenue regulatory second of Teva, generic for We year results laser ANDA mix we've which proprietary have our the XXXX revenue gain focusing role The we believe sales, assuming a a growth up them, both is for approval exciting $XXX for the drive catalyst revenue last Forteo high to is concludes company. you the – have U.S. progress

Operator

[Operator Instructions] Piper We’ll Amsellem go with David first Jaffray. to

Mickey Ingerman

on Ingerman for question. Mickey is David for the Good and taking morning. This thanks

unique group coming a of this of over of over can out spread on XYOSTED volumes secondly are the a Are prescribers? the nature spread And on could far. for the comment some physicians from significant you at the context then step select audience? just provide if or numbers XYOSTED, you number wider of First on – prescription it’s

Bob Apple

Right.

So across would it of doctors so is a there’s over pretty right no large the and -- a write think categories as interestingly far launch pretty Urologists testosterone writing who I audience but regular of there are across always it It’s had states doctors writers written. XYOSTED percentage don't up is make basis, testosterone XYOSTED. well large number large being endocrinologist this are as I and on products X,XXX a writers or physicians products. are endocrinologists, physicians are shows of since also are think three they really obviously – of message all and resonating it the the then There general at the much a point. and scripts I also what writing who steady that who practitioners biggest of writers, broad writing are we've list our then the say write at

it’s continue of turn across you in good So facets, stages some the early the we but big very to of of and utilization know across in the all it’s and physicians. seeing we're facets all see physicians to launch those writers,

As pretty far all that as the think the products step step have. seeing edits testosterone [ph], other edits are we same that I much the

but plans the and that have authorization to have obviously already don't need heavy that through XX% then for some already draws have edit high process the patient know If has we on need everyone testosterone they the a and fortunately to and keep is may you seeing two not if low, step a whether trying we they of you of prove step obviously on really market go XYOSTED. that so know may through counts a the are know plan you in is plans, You to make so depending deficiency. cost, where generic, costs where generic they prior testosterone morning on – you to already to blood we're are

Mickey Ingerman

it, Got you. that’s helpful. Thank

Operator

with We’ll go Jefferies. Anthony Petrone next to

Anthony Petrone

Thanks. to year. the Congratulations start on a good

a Epi. XYOSTED maybe Here I on to have and shift couple

endocrinologists mix, Is just physicians. do mix a detail of out you GP’s. more and in little there there just on or know of the the on have urologist Bob you know just that gate You the

the trying mix. Just a to of get sense

Bob Apple

right probably physicians across been I the and so where urologist, getting it's high mix the are products endocrinologist following writers, it's other to three the where the would written bigger those and think I XXXX testosterone are overall have and question, normal all any general spectrums now our the really is on last We're three it – three from become physicians. practitioners I writing received well decile Yeah, practitioners pretty solid. it's of say mentioned physicians groups I earlier, writing: said say all but by and biggest writers actually probably the all like writers it's and over general

Anthony Petrone

there's there. X, on like that to tier have I of it you of on head XX% be end know the maybe follow XYOSTED think on Do mentioned, lives on a well Thanks would the and as just XX% potential by moment little you maybe to seems Epi. just up and the a of bit for know tier stay of Is coverage sort of and the helpful, again. as you expectations the coverage. one a that exceed That's covered of year end your so it and on your to you more hitting April X you as just terms target. the know way

Bob Apple

Sure.

coverage. So patients would write to we cover co-pay that with support X much plan X that coverage. tier support, the that we targeted co-pay – don't we in We our pretty XXX% of tier have $XXX think up would that any

tier at know too you obviously to standpoint. think we lot far When access in rebate to coming are tier plans plans, that that with the of X, larger to a rebate plans and a have get large those plans. rebate are the to know and mix no of a we providing to have X you then so as PBM's, as a And look costly from we it's we the

of far the guidance pretty good the So as covered. feel we year, where end and of we we we where at we’ll are XX% the of about lives as gave be

really we're where whether have coverage to QX we the I confident and far update sense covered lives number start know QX that. you we you up don't going plans QX X of that to we'll and the the some coverage and better with of effective but I smaller typically will It’s pretty expect plans but hit if in guiding of to the not you happen discussions so start feel just quarter, that's so than think function work. hoping that, some going onboard on that a had as remarks, we haven't we see were we know had you XX% and I'll we good we’re a right more prepared yet that way of that's end with even more the see clearly XX% and know plans know see to You the the come have are now, They a come XX%, QX. a saw as July we'll as the April and you one if really we probably of in know better by know come to

Anthony Petrone

helpful very launch. so quickly just or they is a just in at and injector we side there obviously than know the Very on auto and ahead as just that the you I'm looking wondering, of Epi. Teva also Thanks. should The side, be expected on there numbers, stocking better are on

Bob Apple

which early in back able onto to Epi end that's market junior the they was full the the are the second going you commercial the launch. is still think exactly doing quarter to and the well are expected the is last think third to quarter, that do where launch. bring of I Teva know is, going I where I They launch think they they had and quarter, when that limited disclosed Yeah, be

week-over-week which is still and growth their they in full So we seeing launch. haven't the supplying them but are EpiPens, markets obviously of need of done

their to our pretty rate of As the far devices, we launch in product trying consistently is the there increase expect full continue we'll our at you you far to stocking so year, hopefully are normal of a basically that going of in that know in it's we're significant and a device the devices, ahead but half forecast. course commercial as of their this as to the producing well. of so see know sales stay as and to We're supply some forecasts them, second but the as to we growth in sales and

been the as and both products a do it's So for full start and once good we it's and a are commercial it they both opportunity launch, big been us very of really available see – us. Teva for

Anthony Petrone

you. Thank

Operator

go to Thalmann. with Kaplan Matt We’ll next Ladenburg

Matt Kaplan

morning quarter. good Hi, the and congrats on

Bob Apple

Thanks Matt.

Matt Kaplan

drill you've gotten know just force could market your with see you I with into messaging sales quarter modifications to could. based feedback you that or force XYOSTED. wanted of we – on from with, XYOSTED little do bit out I are if and it the sales guess the to a out enhance more launch that existing with place sales you that there that any now need you your make even terms belt, of down your your a there of the in of further messaging the size under

Bob Apple

as the weeks national far messaging, so had few a Okay, just meeting ago. sales we our as actually

to is planned what show story is the the standpoint, easy them three we a after and to back in PK, message know field to the are they the months very the and get from bring It's is resonating to positive if see coverage. assess physicians question really resonating. a the really it had next and You our hearing from message doctors

that the our the a it targets, lined to we’re of got XYOSTED that get and product sure because they to to is only You – making rest and physician and but all written, don't aspect, that write on get prescription when that's we're and where about so get we know they those so spending to for launch deal, of is you important lot big only to home coverage making most it a we filled know have easy XX% and see it up writers focusing why that's get hammering because time you get you filled. and when it the decile keep to comfortable a that high not get the patient

attributes all patients. message the physicians and resonating absolutely steady those the state, product the So of positive the of are painless, with

emails We’re patience assistant positive. lot with you been saying physician's getting of from a physicians, you know XYOSTED extremely know and the has that experience

So we say to message that part our have much. don't that would really I alter

as I'm second know – sorry, as of it? far your the what was part which question You was

Fred Powell

Modifications.

Matt Kaplan

modification? Any

Bob Apple

XYOSTED’s we’re know of where comfortable modification yeah, are. you – we're the So efforts very we and

and are where You you of the on as have care and say as are about primary endocrinologists know physicians are focus primary heavy a have they all you care really territories, physicians, docs we They testosterone the not primary physicians. would it’s XX expect. that primary care so know urologists, care audience not on health calling and an large I’d men's docs

and/or So place impact you really right feel get think It but the the know the from the with right the more time right if territory. looking expanding assessed adding we'll start we at. rep our lowers number you But until size. potentially the that, we territories know and right are size. really on the we XX the But it's all insurance coverage we right they Obviously of feels now, now windshield know, are we territories, you know in the we few at do we would viable I confident large territories. now you plans – see a it like reps, a

Matt Kaplan

terms urology you of indication, to gears terms development And that? a give more that’s opportunity, a little you can of also pipeline, a color the into product neurology bit that very you the helpful. on well. that little Any product. you Could in market in add that's and Alright, XXXX, moving color a as us the XXXX, then anything bit on maybe just mentioned mentioned a shifting

Bob Apple

product been Yeah, the so. the it’s neurology I or the on last mean on for we’ve one year working

You of know the it we given as pen. results. one strong think our in by thing a we the is you know very have area developing Epi where pens rescue rescue is It’s capabilities

and proprietary trials until we're We out that we a about need pen into we really do pen. so get know population that's one an when meaningful the don’t and know in have we focus more much for area it's know You to lay with give have you we that targeting. an we're a it. neurology for us is so able rescue detail the are the Epi program really want clinical we and to rescue But an on think unmet need excited unmet for you patient Clearly a product. of asset clinical Pfizer,

program, where the detail. pen, other the you for but is rescue an it where stage, early patients and know they and start time. satisfied going urology we the with see again a give that area clinical FDA, but as an it urology what are aren’t the using unmet as to we under the the until meet not know its It’s in one keep we're you so going opportunity currently development, On to with wraps much not there need, is an formalize that we're product,

Matt Kaplan

questions. Thanks for the taking good. Very

Operator

go We’ll Cowen Maughan Bill & to Company. with next

Bill Maughan

been have into remind percent Good or morning paid program XYOSTED and point and congrats XYOSTED of to and programs that place get have the in us question prescriptions this patients’ in assistance? this point at of terms what you hands the is sampling prescriptions at the on copay you of first can My progress.

Bob Apple

I turn the and mean, I’ll of over can part question second Fred. I the the one other handle

far we to first as use so want from copay a we From physicians the the in a sample all assistance, sampling had sampling the standpoint, in patient. forth. that from office new and As program the

is And experience doctor's that see and it patient the one injection, - how that know with week easy painless use, is at So us therapy that they a also they gives another to office. helps typically you of the with it they We that also positive is and physician the how then patients. ask physician painless response new, to and also it is it's is how provide sample easy patient. to see the if use how to

if weeks to for company there the out an we get any that hope they to two patient is they kind Cover time Meds, So is adjudication help sufficient and have when of we get process. weeks And office. nationally physician the to adjudication you submit walk that And therapy that probably and use, e-script, door their electronically recognized of process. process, through the of approved the My called has the it that that with adjudication it’s an in pharmacy written essentially they two know

covered, pretty provided appeal office. has that we that and it’s then of success a commercial person is appeal. help commercial rejection that the rejection insurance, because they then and initially we've if from prior same reversing will provide the hasn’t month drugs insurance is will during need Meds, month that So Cover company, get they information physician’s good there's free one had of and If yet, the the authorizations why physician reason that there and not do that that My we

all it insurance, they so it that's to can’t at anymore. If end doesn't part process Fred. get our then And part have the have the into XYOSTED. have physician as question support products, been of But you any to-date the insurance, making to for the far the over we patient versus free script. if of then again that commercial the scripts and that of I’ll percentage easy a And hopefully know patient know your then as patient turns second of paid you turn obviously what paid

Fred Powell

so for we are and in Sure. increase. at be where prescriptions at, while higher What beginning a that. than percentage was you'd now, below we would of when as and percentage launch hoped seen percentage scripts free happened give as less it expect target coverage you the right a was that I currently aid is and of had the we of can't a we below We its the have mind

XX%. seen to know tell, below quarter. lower time. the than the second you So that the going percentage we've entire first is it can decrease percentage I certainly for the quarter It continue and that over into is

Bob Apple

need our suit already I The it we to diminishes. that which know And think for you at XX%. coverage improves, follows are as that program

So where gets the there and to room covered being out the always going a of script with focused but world so you some would improvement, know time, But their of real back get get done that’s to came the response. on it product and what's the know surveys are when as for as and physicians as really seamless both want you the hear, found so making XXX% physicians and not and we when that you we it happening surveys that They it or the they it especially a that that’s when field. patient some There’s really think at easy a analysts we that's happy filled most what and want that been the feel easy everything physician. so the other as know and write in importantly they for gets that doing. relatively and what were was and far it more by to was it, we've that's the – we're know believe I is not planned the patient physician and it's possible launch. so

Bill Maughan

for understanding was the pregnancy size bit Okay and to and many then efficacy to do terms a as of you help us of current ectopic ectopic what's methotrexate little hoping get of the more these it it is methotrexate color get I pregnancies market. in the Anything how on can patients. maybe

Bob Apple

patient; It’s do scarring they percentage if can methotrexate. of I be invasive pregnant the for obviously patients in majority surgery; if outcomes less for difficulties is tends as get more a the get far getting procedure, to So what to surgical methotrexate better of it any versus the patient the think lead patients there as again.

of again, towards plan we easy But good think the if provided it physician, with that forth. move success in the could really is help I option a towards know more you I care the use of it so and the function And develop, of of an more clinical to the auto a of injector that methotrexate. standard think it office so that of product

is there a ectopic if sure we I'm think a be you and far labeled question. pregnancies part and an benefit having for know auto XXX,XXX year As that I ectopic injector patients, a pregnancy with physicians of about as for both would you indication know the the missed and number, not another

think questions. I hit your I

Bill Maughan

Thank Yeah, you you it. covered very much.

Operator

to James. We’ll next Wilbur go Instructions]. with [Operator Elliot Raymond

Vikram Arun

have Hi, is I on good thanks for taking Elliot, the here. Vikram for This morning. two Arun just questions.

that’s or any if know is you if the from if those and first The new said are were starts. generic refill on XYOSTED for be one read mostly have if you patient they coming on that rates to

Bob Apple

I very have Yeah, refill the been high. mean rates

more know weekly on we Our where that meaningful is of know pleased persistence want we’ll right not its so or is you switches. is are we and a refill to whether patient persistence is see We to new XX% if are in that becoming determine rate rates don't that refill issue, the you area refills seeing patients overall be are the and basis at I really now and we're that very high. pretty we excess continue, or think and happy launch. therapy the an and an with and were persistence rate those very Testosterone where more

We know need to the expect time but it those, attributes, from, think that see you to continue where because some you we product stay coming but more yet, that on persistency have quite therapy more where know been of is the know refills that switch is versus we or whether strong. to the patient, likely not patient know longer don't a overall we new I

Vikram Arun

that's hydroxyprogesterone it, had end AMAG’s points you got its helpful. any the that trial thoughts from failure on removed And to if might wondering reach you just Makena convers any of be know Okay, then the and second, market.

Bob Apple

know QX in a with QX. quarter volume change seen Makena you very is of injectors for strong No, we was us going strong. haven’t auto out I mean The very obviously and any

what as they long the very FDA, still see really really dialog writing, where AMAG with product still forth, with as still the physicians inappropriate for know for term we're than sure are is place the using AMAG. are strong. Makena. FDA far not has the results know seeing the in As is AMAG but of further study its that's give a other we and is commentary a me that you which and this until any question to I’m What we market so

that product efficacy say have you I all us know think I meaningful only study thing to the approved a can a of be clinical would say program robust was which will help that So, factual, that is on AMAG. for with – both and continue is is very I and very Makena strong

Vikram Arun

Alright, thanks.

Operator

the back remarks. closing And further time turn questions. to call I Jack are for Howarth there at this no will

Jack Howarth

thanks call. us conference Jennifer again on Thanks and for today's joining

me you any have you completes XXX-XXX-XXXX. can That call. at reach today's If up follow questions

Operator

conference. That's concludes for today's your We participation. thank you

Antares Pharma (ATRS) 2 May 192019 Q1 Earnings call transcript